亚洲日韩欧美综合-亚洲日韩欧美一区二区在线-亚洲日韩欧美视频-亚洲日韩精品欧美一区二区-国产欧美日韩综合

會員登錄|免費(fèi)注冊|忘記密碼|管理入口 返回主站||保存桌面|手機(jī)瀏覽|聯(lián)系方式|購物車
企業(yè)會員第1年

濟(jì)南誠匯雙達(dá)化工有限公司銷售公司  

各類原料藥及其中間體

搜索
新聞中心
  • 暫無新聞
產(chǎn)品分類
  • 暫無分類
聯(lián)系方式
  • 聯(lián)系人:黃先生
  • 電話:0531-58897087
  • 傳真:0531-58897093
  • QQ:1135136112
站內(nèi)搜索
 
榮譽(yù)資質(zhì)
  • 暫未上傳
友情鏈接
  • 暫無鏈接
首頁 > 供應(yīng)產(chǎn)品 > 伏立康唑 原料藥價格生產(chǎn)廠家CAS
伏立康唑 原料藥價格生產(chǎn)廠家CAS
單價 面議對比
詢價 暫無
發(fā)貨 山東濟(jì)南市付款后3天內(nèi)
過期 長期有效
更新 2017-04-05 15:51
 
詳細(xì)信息
 伏立康唑  原料藥價格生產(chǎn)廠家CAS

CAS: 137234-62-9

英文名稱: Voriconazole

英文同義詞: UK-10949;UK-109496;Vorionazole;VORICONAZOLE;Voriconazole(UK 109496);(2R,3S/2S,3R)-3-(5-FLUORO-4-PYRIMIDINYL)-2-(2,4-DIFLUOROPHENYL)-1-(1H-1,2,4-TRIA;2-(2,4-difluorophenyl)-3-(5-fluoropyrimidin-4-yl)-1-(1h-1,2,4-triazol-1-yl)butan-2-ol;(2R,3S)-2-(2,4-difluorophenyl)-3-(5-fluoropyrimidin-4-yl)-1-(1,2,4-triazol-1-yl)butan-2-ol;(2R,3S)-2-(2,4-DIFLUOROPHENYL)-3-(5-FLUOROPYRIMIDIN-4-YL)-1-(1H-1,2,4-TRIAZOL-1-YL)BUTAN-2-OL;(2R,3S)-2-(2,4-Difluorophenyl)-3-(5-fluoro-4-pyrimidinyl)-1-(1H-1,2,4-triazol-1-yl)-2-butanol

中文同義詞: 伏立康唑;伏立康唑 威凡;(2R,3S)-2-(2,4-二氟苯基)-3-(5-氟嘧啶-4-)-1-(1H-1,2,4-三唑-1-)-2-丁醇;(2R,3S)-2-(2,4-二氟苯基)-3-(5-氟嘧啶-4-)-1-(1H-1,2,4-三唑 -1-)-2-丁醇;伏立康唑/(2R,3S)-2-(2,4-二氟苯基)-3-(5-氟嘧啶-4-)-1-(1H-1,2,4-三唑 -1-)-2-丁醇

CBNumber: CB1160110

分子式: C16H14F3N5O

分子量: 349.31

©2025 濟(jì)南誠匯雙達(dá)化工有限公司銷售公司 版權(quán)所有   技術(shù)支持:化工網(wǎng)   訪問量:6354  
 
主站蜘蛛池模板: | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |